Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy
1. FDA issued a warning letter to Hims & Hers regarding misleading claims. 2. The company's semaglutide products were flagged as misbranded by the FDA. 3. Hims must respond within 15 days outlining corrective steps taken. 4. Stock declined 7.21% following the release of the warning letter. 5. Continued misleading promotion may lead to enforcement actions.